Publicacións en colaboración con investigadores/as de Duke University (1)

2018

  1. Single intravenous dose of oritavancin for treatment of acute skin and skin structure infections caused by gram-positive bacteria: Summary of safety analysis from the phase 3 SOLO studies

    Antimicrobial Agents and Chemotherapy, Vol. 62, Núm. 4